Results Extend Previously Reported Positive Phase 3 SURPASS-ET Study Data, Demonstrating Superior Efficacy Compared with Anagrelide in Hydroxyurea-Resistant or Intolerant Essential Thrombocythemia ...
Ropeginterferon alfa-2b-njft (P1101) achieved durable hematologic responses in ET patients with a manageable safety profile, outperforming anagrelide in the SURPASS-ET trial. P1101 showed a ...
The FDA accepted Besremi's application for essential thrombocythemia, supported by SURPASS-ET and EXCEED-ET trial results, with a review target date of August 30, 2026. Essential thrombocythemia is a ...
The MarketWatch News Department was not involved in the creation of this content. EXCEED-ET Study Results Demonstrate Significant Efficacy, with Consistent Treatment Response Across the Overall ...
EXCEED-ET Study Results Demonstrate Significant Efficacy, with Consistent Treatment Response Across the Overall Essential Thrombocythemia Population Results Extend Previously Reported Positive Phase 3 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results